Moreover, combined treatment with EOAI34 (a USP5 inhibitor) and trametinib (a MEK inhibitor) in CT26 tumor-bearing mice slowed tumor growth and increased CD8+ T-cell infiltration [20] (Table 1). The gene discussed is CD8A; the disease is neoplasm.